Home    Back

Ides    (DrugBank: IdeS)

2 diseases
IDDisease name (Link within this page)Number of trials
64Thrombotic thrombocytopenic purpura2
221Anti-glomerular basement membrane disease1

64. Thrombotic thrombocytopenic purpura    [ 74 clinical trials,   76 drugs,   (DrugBank: 19 drugs),   15 drug target genes,   57 drug target pathways]
Searched query = "Thrombotic thrombocytopenic purpura", "TTP", "Upshaw-Schulman syndrome", "USS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 74 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02854059
(ClinicalTrials.gov)		September 201627/7/2016IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) PatientsA Phase II Pilot Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients With Low ADAMTS13 ActivityPurpura, Thrombotic ThrombocytopenicBiological: IdeS (0.25 mg/kg);Biological: IdeS (0.50 mg/kg)Hansa Biopharma ABUniversity College London HospitalsTerminated18 YearsN/AAll2Phase 2United Kingdom
2EUCTR2016-000249-30-GB
(EUCTR)		14/07/201619/05/2016IDES IN ASYMPTOMATIC TTP PATIENTSA PHASE II PILOT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACODYNAMICS AND PHARMACOKINETICS OF IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) PATIENTS WITH LOW ADAMTS13 ACTIVITY - IDES IN ASYMPTOMATIC ANTIBODY-MEDIATED TTP PATIENTS WITH LOW ADAMTS13 Asymptomatic antibody-mediated thrombotic thrombocytopenic purpura (TTP) with low ADAMTS13 activity
MedDRA version: 19.0;Level: PT;Classification code 10043648;Term: Thrombotic thrombocytopenic purpura;System Organ Class: 10005329 - Blood and lymphatic system disorders ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]		Hansa Medical ABNULLNot Recruiting Female: yes
Male: yes		6Phase 2United Kingdom

221. Anti-glomerular basement membrane disease    [ 1 clinical trial,   3 drugs,   (DrugBank: 1 drug),   0 drug target gene,   0 drug target pathway]
Searched query = "Anti-glomerular basement membrane disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 1 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03157037
(ClinicalTrials.gov)		March 1, 201711/5/2017An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES)An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDESAnti-Glomerular Basement Membrane DiseaseBiological: HMed-IdeSMårten SegelmarkHansa Biopharma ABCompleted18 YearsN/AAll15Phase 2Austria;Czechia;Denmark;France;Sweden